Skip to main content
SpringerLink
Log in

Cancers gynécologiques

  • Compterendu
  • Actualités de l’ASCO 2007
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Alberts DS, Liu PY, Hannigan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955

    Article  PubMed  CAS  Google Scholar 

  2. Alberts DS, Liu PY, Wilczynski S, et al. (2007) Phase III randomized trial of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum-sensitive patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: SWOG protocol S0200. ASCO Annual Meeting Proceedings, abstract 5551

  3. Armstrong DK, Bundy B, Wenzel L, et al. (2006) Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. GOG 172. N Engl J Med 354(1): 34–43

    Article  CAS  Google Scholar 

  4. Bolis G, Scarfone G, Giardina G, et al. (2001) ARGO 96 study group. Carboplatin alone versus carboplatin plus epidoxorubicin as second-line therapy for cisplatin or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81: 3–9

    Article  PubMed  CAS  Google Scholar 

  5. Conte PF, Favalli G, Gadducci A, et al. (2007) Final results of after-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy. ASCO Annual Meeting Proceedings, abstract 5505

  6. Creasman WT, Odicino F, Maisonneuve P, et al. (2003) Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83(Suppl. 1): 79–118

    Article  PubMed  Google Scholar 

  7. Creutzberg CL, Van Putten WL, Koper PC, et al. (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Lancet 355: 1404–1411

    CAS  Google Scholar 

  8. Ferrandina G, Lorusso D, Pignata S, et al. (2007) A randomized phase III study of gemcitabine versus pegylated liposomal doxorubicin in progressive/recurrent ovarian cancer. ASCO Annual Meeting Proceedings, abstract 5506

  9. Gordon AN, Fleagle JT, Guthrie D, et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312–3322

    PubMed  CAS  Google Scholar 

  10. Hogberg T, Rosenberg P, Kristensen G, et al. (2007) A randomized phase III study on adjuvant treatment with radiation ± chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). ASCO Annual Meeting Proceedings, abstract 5503

  11. Keys HM, Roberts JA, Brunetto VL, et al. (2004) A phase III trial of surgery with or without ajunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A GOG study. Gynecol Oncol 92: 744–751

    Article  PubMed  Google Scholar 

  12. Konner JA, Fallon K, Pezzuli S, et al. (2007) A phase II study of intravenous (i.v.) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. ASCO Annual Meeting Proceedings, abstract 5523

  13. Krasner CN, Seiden MV, Fuller Jr. AF, et al. (2007) Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. ASCO Annual Meeting Proceedings, abstract 5521

  14. Lhommé C, Petit T, Largillier R, et al. (2007) Concomitant weekly carboplatin and paclitaxel with pelvic radiotherapy for the treatment of advanced cercical cancer: a FNCLCC gynecologic group phase I trial. ASCO Annual Meeting Proceedings, abstract 5542

  15. Markman M, Bookman MA. (2000) Second-line treatment of ovarian cancer. Oncologist 5: 26–35

    Article  PubMed  CAS  Google Scholar 

  16. Markman M, Bundy BN, Alberts DS, et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma. An intergroup study of the GOG, SWOG, and ECOG. J Clin Oncol 19: 1001–1007

    PubMed  CAS  Google Scholar 

  17. Markman M, Liu PW, Wilczynski S, et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancerafter complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460–2465

    Article  PubMed  CAS  Google Scholar 

  18. Markman M, Liu PW, Wilczynski S, et al. (2006) Survival of ovarian cancer patients treated on SWOG 9701/GOG 178: 12 versus 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum. ASCO Annual Meeting Proceedings, abstract 5005

  19. Moore DH (2006) Chemotherapy for recurrent cervical carcinoma. Curr Opin Oncol 18: 516–519

    Article  PubMed  CAS  Google Scholar 

  20. Orton J, on behalf of ASTEC/EN.5 collaborators (2007) Adjuvant external beam radiotherapy in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. ASCO Annual Meeting Proceedings, abstract 5504

  21. Parmar MK, Ledermann JA, Colombo N, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR 2.2 trial. Lancet 361: 2099–2106

    Article  PubMed  CAS  Google Scholar 

  22. Pautier P, Joly F, Kerbrat P, et al. (2007) Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: final results of a phase II study. ASCO Annual Meeting Proceedings, abstract 5566

  23. Pfisterer J, Plante M, Vergote I, et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC-CTG, and the EORTC-GCG. J Clin Oncol 24: 4699–4707

    Article  PubMed  CAS  Google Scholar 

  24. Rose PG (2006) Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006. Ann Oncol 17(Suppl. 10): 224–229

    Article  Google Scholar 

  25. Sehouli J, Oskay-Oezcelik G, Stengel D, et al. (2007) Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized, two-stage phase II study of the North-Eastern German Society of Gynaecological Oncology. ASCO Annual Meeting Proceedings, abstract 5526

  26. Swart AC, on behalf ICON collaborators (2007) Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). ASCO Annual Meeting Proceedings, abstract 5509

  27. Trimbos JB, Parmar M, Vergote I, et al. (2003) ICON trial 1 and ACTION trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105–112

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’oncologie médicale, CLCC Paul-Strauss, 3, rue de la Porte-de-l’Hôpital, BP 42, F-67065, Strasbourg cedex, France

    T. Petit

Authors
  1. T. Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Petit.

About this article

Cite this article

Petit, T. Cancers gynécologiques. Oncologie 9, 517–520 (2007). https://doi.org/10.1007/s10269-007-0715-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-007-0715-0

Search

Navigation